Evolus, Inc. (NASDAQ:EOLS)’s stock price gapped up prior to trading on Thursday after HC Wainwright raised their price target on the stock from $20.00 to $22.00. The stock had previously closed at $13.93, but opened at $14.43. HC Wainwright currently has a buy rating on the stock. Evolus shares last traded at $14.06, with a volume of 4,274 shares trading hands.

Other equities analysts also recently issued research reports about the company. Mizuho upped their target price on Evolus from $9.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, March 30th. Zacks Investment Research downgraded Evolus from a “buy” rating to a “hold” rating in a research report on Wednesday, February 24th. Cantor Fitzgerald upped their target price on Evolus from $11.00 to $20.00 and gave the company an “overweight” rating in a research report on Monday, February 22nd. Barclays increased their price target on Evolus from $4.00 to $8.00 and gave the stock an “underweight” rating in a research report on Monday, February 22nd. Finally, Stifel Nicolaus increased their price target on Evolus from $11.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, February 19th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. Evolus currently has a consensus rating of “Hold” and an average price target of $13.35.

Several hedge funds have recently modified their holdings of EOLS. Metropolitan Life Insurance Co NY acquired a new stake in shares of Evolus in the 1st quarter valued at $83,000. State Street Corp boosted its holdings in shares of Evolus by 1.1% in the 3rd quarter. State Street Corp now owns 348,776 shares of the company’s stock valued at $1,364,000 after purchasing an additional 3,911 shares in the last quarter. ExodusPoint Capital Management LP acquired a new stake in shares of Evolus in the 3rd quarter valued at $151,000. Squarepoint Ops LLC acquired a new stake in shares of Evolus in the 3rd quarter valued at $40,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Evolus by 9.2% in the 3rd quarter. California State Teachers Retirement System now owns 33,011 shares of the company’s stock valued at $129,000 after purchasing an additional 2,773 shares in the last quarter. 21.66% of the stock is currently owned by hedge funds and other institutional investors.

The stock has a fifty day simple moving average of $12.31 and a two-hundred day simple moving average of $6.41. The stock has a market cap of $613.14 million, a price-to-earnings ratio of -6.86 and a beta of 2.69. The company has a debt-to-equity ratio of 3.25, a quick ratio of 10.03 and a current ratio of 10.42.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, March 23rd. The company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.18). Evolus had a negative net margin of 120.63% and a negative return on equity of 121.11%. Equities analysts expect that Evolus, Inc. will post -1.95 earnings per share for the current fiscal year.

Evolus Company Profile (NASDAQ:EOLS)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Article: Most Active Stocks: Dollar Volume vs Share Volume

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.